FDA Approves Pfizer’s HYMPAVZI for Hemophilia A and B Treatment

On October 11, 2024, Pfizer announced that the U.S. FDA approved HYMPAVZI™ (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric individuals 12 years of age and older with hemophilia A without factor VIII (FVIII) inhibitors, or hemophilia B without factor IX (FIX) inhibitors. 

Phil Gattone, President and CEO of the National Bleeding Disorders Foundation, stated in the press release: “The hemophilia community continually seeks advancements in care that can improve the quality of life for our community members. We greatly appreciate Pfizer’s innovative efforts in developing this novel treatment option that addresses some of the ongoing challenges faced by people with hemophilia A and B. The availability of this therapy represents a powerful step forward in advancing care for more individuals and families in the bleeding disorders community.”

HYMPAVZI is Pfizer’s second hemophilia treatment approved by the FDA this year, demonstrating the company’s ongoing commitment to improving care for people living with hemophilia.

Read the full press release here. 

The information contained in this release is as of October 11, 2024.

Written by Kyla Clark, Director of PR and Communications

Source: National Bleeding Disorders Foundation, October 2024